To present the pioneering concept, Peer and his team encoded the anti-inflammatory protein interleukin-10 into mRNA and ...

Understanding the link between gut health and psoriasis opens new avenues for treatment and highlights the need for comprehensive care approaches that encompass both dermatological and gastrointestina ...

SAN FRANCISCO -- More adults with moderate-to-severe Crohn's disease (CD) reached clinical remission after 6 months on ...

SAN FRANCISCO -- The pediatric Crohn's disease exclusion diet was associated with clinical remission for children with good ...

IBD Aware, a wearable medical device in development for patients with inflammatory bowel disease, aims to improve disease ...

Let's dive deep into a topic that isn’t getting enough shine – Crohn's disease and how it's hitting the Black community.

Eli Lilly (NYSE:LLY) reported positive results from an open-label study of its drug Omvoh in the treatment of moderately to severely active Crohn's disease. The study, called VIVID-2, showed that the ...

INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY), a pharmaceutical giant with a market capitalization of $783.7 billion ...

Eli Lilly And Cao (NYSE:LLY) announced the results from the VIVID-2 open-label extension study of Omvoh (mirikizumab-mrkz).

The company is currently preparing for Phase III trials to further assess the efficacy and safety of the agent in identifying active inflammation in individuals with Crohn's disease. Credit: ...

More than 90% of Omvoh-treated patients who were in clinical remission at one year sustained it with two years of continuous treatment Nearly 90% of ...

Mozart Therapeutics, the leading developer of CD8 Treg network modulators in autoimmune disease, announces the presentation ...